Effect of budesonide inhalation joint montelukast in the treatment of children with mycoplasma pneumonia cough
10.3760/cma.j.issn.1008-6706.2016.08.025
- VernacularTitle:布地奈德联合孟鲁斯特钠治疗小儿支原体肺炎的疗效观察
- Author:
Xiuyuan LUO
;
Yangbo HU
- Publication Type:Journal Article
- Keywords:
Budesonide inhalation;
Montelukast;
Mycoplasma pneumonia cough;
Cough;
Clinical efficacy
- From:
Chinese Journal of Primary Medicine and Pharmacy
2016;23(8):1211-1214
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effect of budesonide inhalation joint montelukast in the treatment of children with mycoplasma pneumonia cough.Methods 176 children with mycoplasma pneumonia cough were chosen.According to the order of admission,they were divided into observation group and control group.Control group was given montelukast sodium chewable tablets treatment,the observation group was given budesonide inhalation on the basis of treatment of control group.After treatment,the efficacy,prognosis and compliance were observed.Results Before treatment,the cough scores between the two groups had no significant difference (P>0.05).After treatment, the degree of cough in the two groups were significantly improved, the cough score of the observation group from (7.4 ±2.2)points decreased to (1.5 ±0.6)points (t=24.271,P<0.05);the cough score of the control group from (7.5 ±2.3)points decreased to (5.4 ±1.8)points (t=6.745,P<0.05);and the cough score of the observation group was significantly lower than the control group,the difference was statistically significant (t =19.282,P <0.05).The total effective rate of the observation group was 93.18%,which of the control group was 73.86%,the difference was statistically significant (χ2 =3.446,P<0.05).The incidence rate of adverse reactions in the observa-tion group was 4.55%,which in the control group was 11.36%,but there was no significant difference between two groups (P>0.05).The relapse rate of the observation group was 7.95%,which was significantly lower than 18.18%of the control group, the difference between the two groups was statistically significant ( P <0.05 ) .Conclusion Budesonide inhalation joint montelukast in the treatment of mycoplasma pneumonia cough has significant effect,it has less adverse effects,good safety,and children without any discomfort,so it worthy of clinical application.
